Kevin Collen, MD
Psychiatry · Brentwood, TNNPI 1235153446
Payments from drug & device makers
Across 50 payments — averaging $29.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$238
- Janssen Scientific Affairs, LLC$200
- Neurocrine Biosciences, Inc.$197
- AbbVie$135
- Otsuka America Pharmaceutical, Inc.$108
- Alkermes, Inc.$101
- plus $484 from 13 others
What the payments were for
- Consulting fees$20014%
- Food & beverage$1,26486%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 6 | $238 |
| Janssen Scientific Affairs, LLC | 1 | $200 |
| Neurocrine Biosciences, Inc. | 5 | $197 |
| AbbVie(2 entities) | 6 | $135 |
| Otsuka America Pharmaceutical, Inc. | 5 | $108 |
| Alkermes, Inc. | 5 | $101 |
| Sunovion Pharmaceuticals Inc. | 4 | $85 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 3 | $78 |
| Ironshore Pharmaceuticals Inc. | 2 | $43 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $40 |
| Vanda Pharmaceuticals Inc. | 1 | $33 |
| Lundbeck LLC | 1 | $32 |
| Neos Therapeutics, LP | 2 | $30 |
| E.r. Squibb & Sons, L.L.C. | 1 | $29 |
| Eisai Inc. | 2 | $29 |
| Tris Pharma Inc | 1 | $25 |
| Corium, LLC | 1 | $21 |
| Idorsia Pharmaceuticals US Inc | 1 | $21 |
| Axsome Therapeutics, Inc. | 1 | $19 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$1,464 in reported general payments places this provider in the 70th percentile of 503 psychiatry providers in Tennessee.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| AustedoDeutetrabenazine | 12 | $82,404 |
| Desvenlafaxine Succinate ErDesvenlafaxine Succinate | 11 | $2,344 |
| Quetiapine Fumarate | 61 | $1,616 |
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 12 | $1,518 |
| Aripiprazole | 29 | $1,454 |
| Trazodone Hcl | 52 | $687 |
| Buspirone Hcl | 18 | $415 |
| Bupropion XlBupropion Hcl | 19 | $373 |
| Lamotrigine | 30 | $370 |
| Divalproex Sodium | 13 | $358 |
| Mirtazapine | 27 | $354 |
| Fluoxetine Hcl | 26 | $211 |
| Venlafaxine Hcl | 12 | $205 |
| Donepezil Hcl | 20 | $200 |
| Escitalopram Oxalate | 13 | $182 |
Paid to pharmacies, not to this prescriber.
Other psychiatry in Brentwood
- Jonathan BeckerBrentwood$261K
- Rakesh AminNashville$3M
- Brian BonfardinJohnson City$2.6M
- Paul NewhouseNashville$1.4M
- John FenleyJohnson City$1.4M
- Anita VarmaMemphis$1.3M
- Patricia AndrewsNashville$748K
- David SnowMaryville$605K
- Robert FallisNashville$241K
- James HartFranklin$226K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.